{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=120", "query": { "intervention": "CTRL", "page": 120 }, "page_size": 10 }, "pagination": { "page": 120, "page_size": 10, "total_count": 26684, "total_pages": 2669, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=121&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=119&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:28:05.303Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05374499", "title": "Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post Operative Pain" ], "interventions": [ { "name": "Liposomal bupivacaine", "type": "DRUG" }, { "name": "0.5% bupivacaine with 1:100,000 epinephrine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 85, "start_date": "2022-09-01", "completion_date": "2024-05-01", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374499" }, { "nct_id": "NCT02255799", "title": "Multicenter Evaluation of Memory Remediation After TBI With Donepezil", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Traumatic Brain Injury", "Memory Deficits" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 75, "start_date": "2013-09-01", "completion_date": "2024-12-04", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Elkins Park", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255799" }, { "nct_id": "NCT04191499", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2020-01-29", "completion_date": "2027-11-15", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 10, "location_summary": "Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191499" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT02609399", "title": "ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Oseltamivir", "type": "DRUG" }, { "name": "Peramivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 180, "start_date": "2015-11-01", "completion_date": "2018-05-31", "has_results": true, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Baltimore, Maryland", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02609399" }, { "nct_id": "NCT00836199", "title": "NicVAX/Placebo as an Aid for Smoking Cessation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Smoking Cessation", "Smoking", "Tobacco Cessation" ], "interventions": [ { "name": "NicVAX vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nabi Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1000, "start_date": "2009-10", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-05-09", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Newport Beach, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00836199" }, { "nct_id": "NCT03436199", "title": "Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Walking Impairment", "Multiple Sclerosis" ], "interventions": [ { "name": "ADS-5102, 137 mg", "type": "DRUG" }, { "name": "ADS-5102, 274 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Adamas Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 558, "start_date": "2018-03-29", "completion_date": "2019-12-10", "has_results": true, "last_update_posted_date": "2021-12-21", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 78, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436199" }, { "nct_id": "NCT03994731", "title": "Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Pegloticase", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "folic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "gout flare prophylaxis regimen", "type": "DRUG" }, { "name": "fexofenadine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2019-06-13", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03994731" }, { "nct_id": "NCT02543931", "title": "Curcuma Longa L in Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Meriva", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-11", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543931" }, { "nct_id": "NCT02708095", "title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2016-03-24", "completion_date": "2017-11-09", "has_results": true, "last_update_posted_date": "2018-11-21", "last_synced_at": "2026-11-15T12:28:05.303Z", "location_count": 27, "location_summary": "Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02708095" } ] }